Detalhe da pesquisa
1.
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.
N Engl J Med
; 381(24): 2315-2326, 2019 12 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31826340
2.
Pharmacokinetic-pharmacodynamic guided optimisation of dose and schedule of CGM097, an HDM2 inhibitor, in preclinical and clinical studies.
Br J Cancer
; 125(5): 687-698, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34140638
3.
Revisiting dosing regimen using PK/PD modeling: the MODEL1 phase I/II trial of docetaxel plus epirubicin in metastatic breast cancer patients.
Breast Cancer Res Treat
; 156(2): 331-41, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-27002506
4.
A phase Ia/Ib clinical trial of metronomic chemotherapy based on a mathematical model of oral vinorelbine in metastatic non-small cell lung cancer and malignant pleural mesothelioma: rationale and study protocol.
BMC Cancer
; 16: 278, 2016 Apr 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-27094927
5.
Model-based assessment of erlotinib effect in vitro measured by real-time cell analysis.
J Pharmacokinet Pharmacodyn
; 42(3): 275-85, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25822652
6.
Contribution of machine learning to tumor growth inhibition modeling for hepatocellular carcinoma patients under Roblitinib (FGF401) drug treatment.
CPT Pharmacometrics Syst Pharmacol
; 11(8): 1122-1134, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35728123
7.
Integration of Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy into Model-Informed Dose Selection in Oncology First-in-Human Study: A Case of Roblitinib (FGF401).
Clin Pharmacol Ther
; 112(6): 1329-1339, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36131557
8.
Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia.
Clin Cancer Res
; 28(5): 870-881, 2022 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34862243
9.
Translational Modeling of Anticancer Efficacy to Predict Clinical Outcomes in a First-in-Human Phase 1 Study of MDM2 Inhibitor HDM201.
AAPS J
; 23(2): 28, 2021 02 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33554304
10.
A framework to guide dose & regimen strategy for clinical drug development.
CPT Pharmacometrics Syst Pharmacol
; 10(11): 1276-1280, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34562310
11.
Pharmacokinetics and Pharmacodynamics-Based Mathematical Modeling Identifies an Optimal Protocol for Metronomic Chemotherapy.
Cancer Res
; 77(17): 4723-4733, 2017 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28655786
12.
Modeling therapeutic response to radioiodine in metastatic thyroid cancer: a proof-of-concept study for individualized medicine.
Oncotarget
; 8(24): 39167-39176, 2017 Jun 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-28389624
13.
Metabolic Profiling of Human Long-Term Liver Models and Hepatic Clearance Predictions from In Vitro Data Using Nonlinear Mixed-Effects Modeling.
AAPS J
; 19(2): 534-550, 2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28050713
14.
Taxanes in paediatric oncology: and now?
Cancer Treat Rev
; 32(2): 65-73, 2006 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-16497442
15.
Revisiting Dosing Regimen Using Pharmacokinetic/Pharmacodynamic Mathematical Modeling: Densification and Intensification of Combination Cancer Therapy.
Clin Pharmacokinet
; 55(8): 1015-25, 2016 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-26946136
16.
Mathematical Modeling of Cancer Immunotherapy and Its Synergy with Radiotherapy.
Cancer Res
; 76(17): 4931-40, 2016 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27302167
17.
Preclinical pharmacokinetics, pharmacodynamics, and efficacy of RG7116: a novel humanized, glycoengineered anti-HER3 antibody.
Cancer Chemother Pharmacol
; 75(4): 837-50, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25702049
18.
Physiologically based pharmacokinetic modeling of CYP3A4 induction by rifampicin in human: influence of time between substrate and inducer administration.
Eur J Pharm Sci
; 56: 1-15, 2014 Jun 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-24530864
19.
Metronomics chemotherapy: time for computational decision support.
Cancer Chemother Pharmacol
; 74(3): 647-52, 2014 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-25082520
20.
Translational PK/PD modeling for cardiovascular safety assessment of drug candidates: Methods and examples in drug development.
J Pharmacol Toxicol Methods
; 70(1): 73-85, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24879942